Next Article in Journal
Loading IR820 Using Multifunctional Dendrimers with Enhanced Stability and Specificity
Next Article in Special Issue
Amorphous Nanosuspensions Aggregated from Paclitaxel–Hemoglobulin Complexes with Enhanced Cytotoxicity
Previous Article in Journal
Effect of Lipid Additives and Drug on the Rheological Properties of Molten Paraffin Wax, Degree of Surface Drug Coating, and Drug Release in Spray-Congealed Microparticles
Previous Article in Special Issue
Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(3), 76; https://doi.org/10.3390/pharmaceutics10030076

Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement

1
Guangzhou Guocaoxiafang Biotechnology Co. Ltd., No. 3 Luoxuan 4th Road, Guangzhou International Biotech Island, Guangzhou 510320, China
2
Department of Pharmacy, School of Pharmacy, No. 601 West Huangpu Avenue, Jinan University, Guangzhou 510632, China
*
Author to whom correspondence should be addressed.
Received: 10 June 2018 / Revised: 25 June 2018 / Accepted: 25 June 2018 / Published: 28 June 2018
Full-Text   |   PDF [3506 KB, uploaded 28 June 2018]   |  

Abstract

Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin/chitosan nanoparticles (ccNPs) for oral delivery of RXF in order to enhance the oral bioavailability. RXF-loaded ccNPs (RXF-ccNPs) were prepared by cyclodextrin inclusion followed by complexation with chitosan. RXF-ccNPs were fully characterized by particle size, morphology and in vitro drug release. The oral delivery efficacy and transepithelial transport potential were evaluated by pharmacokinetics, in situ single-pass intestinal perfusion, cellular uptake and ex vivo imaging. The resulting RXF-ccNPs were around 165 nm in particle size with a narrow distribution. The oral bioavailability of RXF was enhanced by 2.6 folds through ccNPs compared to RXF suspensions in rats. It was shown that RXF-ccNPs could improve the intestinal permeability of RXF, increase the cellular uptake of RXF and facilitate its transport across the absorptive epithelia. The results indicate that our developed ccNPs based on sulfobutylether-β-cyclodextrin and oligochitosan are a promising vehicle to orally deliver poorly water-soluble drugs over and above RXF. View Full-Text
Keywords: raloxifene; bioavailability; nanoparticles; cyclodextrin; chitosan; electrostatic complexation raloxifene; bioavailability; nanoparticles; cyclodextrin; chitosan; electrostatic complexation
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wang, Z.; Li, Y. Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement. Pharmaceutics 2018, 10, 76.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top